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Valproate is a drug widely used to treat epilepsy, bipolar disorder, and occasionally to
prevent migraine headache. Despite its clinical efficacy, prenatal exposure to valproate is
associated with neurodevelopmental impairments and its use in children and adults was
associated with rare cases of reversible brain atrophy and ventricular enlargement. To
determine whether valproate use is related with structural brain changes we examined
through a cross-sectional study cortical and subcortical structures in a group of 152
people with epilepsy and a normal clinical brain MRI. Patients were grouped into those
currently using valproate (n = 54), those taking drugs other than valproate (n = 47), and
drug-naïve patients (n = 51) at the time of MRI, irrespectively of their epilepsy syndrome.
Cortical thickness and subcortical volumes were analyzed using Freesurfer, version 5.0.
Subjects exposed to valproate (either in mono- or polytherapy) showed reduced cortical
thickness in the occipital lobe, more precisely in the cuneus bilaterally, in the left lingual
gyrus, and in left and right pericalcarine gyri when compared to patients who used other
antiepileptic drugs, to drug-naïve epilepsy patients, and to healthy controls. Considering
the subgroup of patients using valproate monotherapy (n = 25), both comparisons
with healthy controls and drug-naïve groups confirmed occipital lobe cortical thickness
reduction. Moreover, patients using valproate showed increased left and right lateral
ventricle volume compared to all other groups. Notably, subjects who were non-valproate
users at the time of MRI, but who had valproate exposure in the past (n= 27) did not show
these cortical or subcortical brain changes. Cortical changes in the posterior cortex,
particularly in the visual cortex, and ventricular enlargement, are present in people with
epilepsy using valproate, independently from clinical and demographical variables. These
findings are relevant both for the efficacy and adverse events profile of valproate use in
people with epilepsy.
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INTRODUCTION
Valproate (VPA) is a drug widely used to treat epilepsy, bipolar
disorder, and occasionally to prevent migraine headache. VPA is
a first-line antiepileptic drug (AED) in the treatment of Genetic
Generalized Epilepsies (GGE) with established efficacy for
absence, tonic-clonic and myoclonic seizures (1–3). VPA is also
particularly effective in reducing the photoparoxysmal response
in various epilepsy syndromes (4–6), but the mechanism
whereby photosensitivity is abolished is still unknown. Possible
effects of VPA on occipital cortical hyperexcitability have
been demonstrated in migraine (7–9), though its mechanisms
of action are still debated. Despite its clinical efficacy, its
use in females must be carefully evaluated since recent
evidence shows that prenatal exposure to valproate is associated
with neurodevelopmental impairments, impaired language and
intellectual abilities and also with structural brain cortical
changes, suggesting an effect of this drug on the prenatal brain
(10, 11). In children and adults, valproate use was associated with
rare cases of reversible brain atrophy and ventricular enlargement
with accompanying cognitive impairment or parkinsonism (12–
14). In Alzheimer’s Disease, valproate use was also related to
accelerated brain volume loss, in particular with ventricular
enlargement and hippocampal atrophy, and greater cognitive
impairment (15, 16). Recently, Pardoe and colleagues evaluated
brain structural measures in seven patients with epilepsy taking
valproate compared to normal controls and to people with
epilepsy not taking valproate (all males): they found that
total brain volume, white matter volume, and parietal cortical
thickness were reduced in the valproate group relative to controls
and non-valproate users; in addition, when comparing past-
valproate users with patients who had never taken valproate,
no differences in brain structures emerged, suggesting that
valproate-related alterations were transient and reversible (17).
The largest published neuroimaging study of epilepsy identified
patterns of shared gray matter reduction across epilepsy
syndromes, informing our understanding of epilepsy as a
network disorder (18). However, this study had not investigated
the possible effects of antiepileptic drugs on brain structures.
In this study, we analyzed structural MRI brain scans from
a large cohort of people with epilepsy in order to determine
whether VPA use is associated with cortical and subcortical
brain changes.
METHODS
Participants and Study Population
We retrospectively reviewed the entire cohort of people with
epilepsy who underwent an MRI study for various research
projects between May 2007 and April 2017 at the Department of
Neuroscience (total of 354 patients). We included only subjects
with normal structural brain MRI on conventional diagnostic
protocol at 3 Tesla and absence of intellectual disability (full-
scale IQ > 80) and psychiatric comorbidities. We excluded
participants with a progressive disease (e.g., Rasmussen’s
encephalitis, progressive myoclonus epilepsy), malformations
of cortical development, hippocampal sclerosis, tumors or
previous neurosurgery, as well as patients with developmental
and epileptic encephalopathies. We therefore focused on a
final pool of 152 people with epilepsy. Sixty-five patients had
a diagnosis of Genetic Generalized Epilepsy (GGE) and 87
patients had a diagnosis of focal epilepsy, according to the
definitions of the Commission onClassification and Terminology
of the International League Against Epilepsy (19, 20). Patients
were categorized with a focal epilepsy according to interictal
or ictal EEG abnormalities and concordant clinical seizure
semiology. Participants were included in the GGE group if they
presented with tonic-clonic, absence, or myoclonic seizures with
generalized spike-wave discharges on EEG. All patients included
in the study had a video-EEG recording/monitoring confirming
the clinical diagnosis.
Patients were grouped into those currently taking valproate
(VPA+), those who were not valproate users (VPA-), and
drug-naïve patients at the time of MRI, irrespectively of their
epilepsy syndrome.
Figure 1 outlines the study flow-chart and the final
study population.
For secondary analyses and in order to evaluate the effect of
VPA use in mono- or polytherapy regimens, VPA+ patients were
classified into subjects using VPA monotherapy and those taking
VPA in polytherapy. No subject used drugs other than AEDs at
the time of MRI.
To evaluate possible correlations between VPA exposure and
brain morphometry measures, we recorded for each patient the
VPA total daily dose, the plasma concentration of VPA, and the
length of VPA exposure (months). Demographic data and clinical
information such as duration of epilepsy, age of epilepsy onset,
past antiepileptic drug prescriptions, type and number of AEDs at
MRI, and treatment response were also collected for each patient.
For group comparisons, 40 volunteers were recruited as
healthy controls (HC). HC had no history of neurological
diseases or past valproate use, or family history of epilepsy, and
had normal structural neuroimaging. Moreover, all controls had
a normal EEG since they were recruited for previous EEG-fMRI
co-registration study protocols by our group.
MRI Acquisition
All subjects were studied with the same MRI scanner, sequences,
and protocol across the study period. Three-dimensional (3D)
T1-weighted MRI images were acquired using a 3 Tesla Philips
Intera MRI scanner (Best, The Netherlands). A SPGR pulse
sequence [echo time (TE) = 4.6, repetition time (TR) = 9.9ms]
was used. One hundred seventy contiguous sagittal slices were
acquired (voxel size = 1 × 1 × 1mm) and field of view was
240mm with a matrix size of 256 × 256 × 170. A T2-weighted
axial scan was also acquired to allow visual determination of
vascular burden or tissue abnormalities.
Statistical Analysis of Patients’ Variables
Demographic and clinical characteristics of the subjects were
analyzed using SPSS software 26.0 (SPSS Statistics, IBM,
Chicago, IL). Independent samples t-tests were used to compare
continuous variables and chi-square was used to compare
categorical variables between groups.
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FIGURE 1 | Study flow-chart. See text for inclusion/exclusion criteria. VPA+,
patients using valproate at the time of MRI study. VPA-, patients using
antiepileptic drugs other than valproate.
MRI Cortical Thickness and Subcortical
Volume Analyses
Scans were analyzed using a standardized image toolbox
(Freesurfer, version 5.0) (21), quality assurance (outlier detection
based on inter quartile of 1.5 standard deviations along with
visual inspection of segmentations), and statistical methods.
Visual inspections of subcortical and cortical segmentations were
conducted following standardized ENIGMA protocols (http://
enigma.usc.edu), used in prior genetic studies of brain structure
(22, 23), and large-scale case-control studies of epilepsy (18) and
neuropsychiatric illnesses (24, 25). Analysts (MT; AEV) were
blind to participant diagnoses. Briefly, as previously detailed
the pipeline involves removal of non-brain tissue, automated
Talaraich transformation, segmentation of white matter, and gray
matter, tessellation of gray/white matter boundary, automated
correction of topology defects, surface deformation to form
the gray/white matter boundary and gray/cerebrospinal fluid
boundary, and parcellation of cerebral cortex (26). Cortical
thickness estimates were then calculated as the distance between
the gray/white matter border and the pial surface at each
vertex. Cortical thickness values were averaged over frontal,
temporal, parietal, occipital, and insular lobes. In addition,
single value labels extracted based on an automatic algorithm
(27, 28) were calculated for more precise analyses (34 regions
for each hemisphere). Subcortical volumes were calculated with
FreeSurfer’s automated procedure for volumetric measures. Each
voxel in the normalized brain volume was assigned to one label
using a probabilistic atlas obtained from a manually labeled
training set (29). The labels adopted for the analysis included the
putamen, caudate nucleus, globus pallidus, nucleus accumbens,
thalamus, amygdala, hippocampus, and the ventricular system.
Statistical analyses were performed using SPSS software
26.0 (IBM, Chicago, IL). To compare cortical measures
between groups, we conducted a univariate ANCOVA with
each neuroanatomical value as the dependent variable, group
diagnosis as fixed factor, and age, gender, intracranial volume
(ICV), and disease duration (if applicable) as covariates.
False discovery rate (FDR) was used to correct for multiple
comparisons and a threshold of p < 0.05, estimated using
SPSS, according to Benjamini and Hochberg methods (30), was
considered statically significant.
RESULTS
One hundred fifty-two patients were finally evaluated for cortical
and subcortical measures. Mean age of the patients at MRI
considering the whole epilepsy group was 24 ± 5.2 years;
mean disease duration was 8.2 years (± 3.4; range 0.5–10); 77
were females.
Table 1 reports the different study groups according to VPA
use. Patients using VPA at the time of MRI (VPA+) were
54 (mean VPA dose = 900 mg/day). The median exposure
time was 40 months (range: 1–250 months). The mean plasma
concentration of VPA was 57.8 ug/ml (median 63 ug/ml;
range 30–98 ug/ml). The VPA+ group consisted of 25 patients
on monotherapy and 29 patients using VPA in polytherapy
regimens (median number of AEDs = 2). There were 47 VPA-
patients taking different AEDs in mono or polytherapy regimens
(median number of AEDs = 2). Fifty-one patients were drug-
naïve at the time of the MRI study. The number of AEDs
and treatment response were comparable between VPA+ and
VPA- groups. Antiepileptic drugs used by non-VPA users (n
= 47) and by VPA+ patients in polytherapy are reported
in Supplementary Table 1 (numbers of patients with specific
drugs were too small to allow sub-analysis for other single
specific AEDs).
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TABLE 1 | Demographic and clinical variables of the different groups according to valproate (VPA) treatment.
VPA users (VPA+) non-VPA users (VPA-) Drug-naïve Healthy controls p
N. of subjects 54 47 51 40
Female gender % 39% 53% 49% 52% n.s.
Age (years), means ± sd 23.2 ± 4.7 30.2 ± 8.2 21.5 ± 2.7 25.5 ± 5.7 < 0.01*
Disease duration (years), mean 8.6 12.6 4.9 – < 0.01**
Patients with GGE (%) 32 (59%) 9 (19%) 24 (47%) – < 0.01*
Patients with Focal Epilepsy (%) 22 (41%) 38 (81%) 27 (53%) – < 0.01*
Patients with TLE 4 17 7 –
Patients with F/I/C lobe epilepsy 18 18 19 –
Patients with P/O lobe epilepsy 0 3 1 –
Patients on mono-therapy (%) 25 (46%) 15 (32%) – – n.s.
Median number of AEDs (mode) 2 (1) 2 (1) – – n.s.
Number of patients with drug-resistant epilepsy (%) 26 (48%) 28 (59%) – – n.s.
Valproate mean daily dose (median), mg 900 (1,000) – – –
VPA+, valproate users; VPA-, non-VPA users; TLE, temporal lobe epilepsy; F, frontal; I, insular; C, central; P, parietal; O, occipital.
*Non-VPA users were older and showed more frequently a “focal epilepsy phenotype” respect with other patients’ groups.
**Drug-naïve patients had a shorter disease duration respect with other epilepsy groups.
Cortical Thickness Analyses According to
Valproate Exposure
For all analyses, disease duration (apart from age, gender and
ICV) was included as covariate of no interest to rule out a possible
effect of this variable on brain structural results.
Direct comparison between VPA- (n =47) and HC groups,
and between VPA- and “drug-naïve” patients (n = 51) did not
reach any significant differences, either at the lobar level, or for
any cortical parcellation.
Table 2 show the main results and the between-groups
significant comparisons. The VPA+ group (n = 54) showed
reduced cortical thickness compared to the VPA- group within
the occipital lobe (F = 6, p = 0.016). More precisely, cortical
thickness reduction was found in left (F = 5.6, p = 0.020) and
right (F = 5.8, p= 0.019) cuneus, in left (F = 6.7, p= 0.014) and
right (F = 5.5, p = 0.020) lingual gyrus, and in right (F = 5.5, p
= 0.020) pericalcarine gyrus (Figure 2). We repeated the analysis
adding also the “epilepsy type” (focal epilepsy/GGE) as covariate
confirming these results (Supplementary Table 2).
A similar pattern of cortical thickness differences emerged
when comparing VPA+ vs. drug-naïve epilepsy patients (n= 51):
this analysis revealed thickness reduction in occipital lobe (F =
20, p < 0.001). In particular in left (F = 10.7, p = 0.001) and
right cuneus (F = 15.9, p < 0.001), in left lingual gyrus (F = 15,
p < 0.001), in left (F = 20, p < 0.001) and right (F = 16, p <
0.001) pericalcarine cortex (Figure 3). Notably these two groups
were matched for epilepsy type, without significant differences
by syndrome (GGE or focal epilepsies). Occipital lobe cortical
thickness reduction was also revealed in VPA+ compared to HC
(F = 11.5, p= 0.001).
Finally, a subgroup analysis considering only patients using
VPA monotherapy (n = 25) with respect to all other groups
confirmed the occipital lobe cortical thickness reduction (in
particular pericalcarine cortex) in VPA users (see Table 2).
Since dose-dependency has been reported in previous
studies to increase the risks of congenital anomalies for VPA,
TABLE 2 | Significant cortical thickness analyses results.
Group comparisons Hemisphere Cortical thickness
measure (mm)
F p
VPA+ vs. VPA- VPA+ VPA-





















lingual gyrus L 1.5884 1.6217 5.5 0.020
VPA+ vs. Drug-naive VPA+ Drug-naive






















VPA+ vs. HC VPA+ HC
Occipital lobe 1.8992 1.9632 11.5 0.001




Occipital lobe 1.9315 1.9632 7 0.001




Occipital lobe 1.9315 2.0298 7.1 0.001
pericalcarine gyrus L 1.6372 1.7397 14.5 0.000
For each group comparison, only statistically significant cortical thickness measure (mm)
for each subgroup are included; F and p value are reported as results of statistical analysis.
VPA+, valproate users; VPA-, non-VPA users; HC, healthy controls; Mono, monotherapy.
and especially at doses above 800 mg/day (31), we also
considered these possible dose-effects on cortical and subcortical
brain measures. No correlations were found between cortical
Frontiers in Neurology | www.frontiersin.org 4 July 2020 | Volume 11 | Article 622
Tondelli et al. Valproate and Brain Structure Change
FIGURE 2 | Cortical thickness difference between valproate users and non-valproate users. Surface brain template showing regions of cortical thinning in valproate
users compared to non-valproate users. Brain images are generated using EnigmaViewer (https://www.nitrc.org/projects/enigmaviewer_20/); strength (color) of heat
map is determined by the size of the regional effect size estimate. Effect size estimates (partial eta squared, y-axis) for cortical thickness differences across all brain
regions is showed on the bar plots. Brain regions with significant differences between groups (p < 0.05 FDR; ANCOVA analysis adjusted for age, sex, disease
duration, and intracranial volume) are reported on the x-axis. Lh, left hemisphere; Rh, right hemisphere.
FIGURE 3 | Cortical thickness difference between valproate users and drug-naïve patients. Surface brain template showing regions of cortical thinning in valproate
users compared to drug-naïve patients. Brain images are generated using EnigmaViewer (https://www.nitrc.org/projects/enigmaviewer_20/); strength (color) of heat
map is determined by the size of the regional effect size estimate. Effect size estimates (partial eta squared, y-axis) for cortical thickness differences across all brain
regions is showed on the bar plots. Brain region with significant differences between groups (p < 0.05 FDR; ANCOVA analysis adjusted for age, sex, disease duration,
and intracranial volume) are reported on the x-axis. Lh, left hemisphere; Rh, right hemisphere.
thickness measures and VPA total daily dose and VPA plasma
concentration. Furthermore, no differences emerged when
comparing VPA+ patients classified according to VPA total daily
dose< or> 800mg. Finally, no correlations were found between
the length of VPA exposure (months) and cortical measures.
Subcortical Structures Analysis According
to Valproate Exposure
As for cortical measures, direct comparison between VPA- and
healthy controls and between VPA- and drug-naïve patients did
not show any significant differences for subcortical structures.
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TABLE 3 | Significant results from subcortical structure analyses.
Group comparisons Hemisphere Volume measure (mm3) F p
VPA+ vs. VPA- VPA+ VPA-
Lateral ventricle L 7,162.71 5,436.5442 17 0.000
R 6,484.076 5,382.4883 12.2 0.001
VPA+ vs. Drug-naive VPA+ Drug-naive
Lateral ventricle L 7,162.71 4,857.9319 12 0.001
R 6,484.076 4,665.7277 12 0.001
VPA+ vs. HC VPA+ HC
Lateral ventricle L 7,162.71 5,241.2211 12 0.001
R 6,484.076 5,080.9842 12 0.001
Pallidum R 1,472.9045 1,551.3053 11.4 0.001




Lateral ventricle L 6,938.2818 5,241.2211 7 0.001




Lateral ventricle L 6,938.2818 4,857.9319 6.4 0.001
R 6,361.3636 4,665.7277 6 0.001
For each group comparison, only statistically significant measure (mm3 ) for each subgroup
are included; F and p value are reported as results of statistical analysis.
VPA+, valproate users; VPA-, non-VPA users; HC, healthy controls; Mono, monotherapy.
On the other hand, the VPA+ group showed increased left
(F = 17, p < 0.001) and right lateral (F = 12.2, p = 0.001)
ventricle volume compared to VPA- (Table 3, Figure 4). Left (F
= 12, p = 0.001) and right lateral (F = 12, p = 0.001) ventricles
were also larger in the VPA+ vs. drug-naïve patients. The direct
comparison between VPA+ and HC showed increased left (F =
20.3, p < 0.001) and right (F = 20.9, p < 0.001) lateral ventricle
volume and also a reduction in the volumes of the right pallidum
(F= 11.4, p= 0.001) and left hippocampus (F= 12.2, p= 0.001).
We repeated the analysis adding also epilepsy type as covariate
and the results did not change (Supplementary Table 2). The
same difference emerged when comparing the VPAmonotherapy
subgroup with HC and with drug-naïve patients.
As for cortical thickness analysis, no correlations were found
between subcortical measures and VPA total daily dose or VPA
plasma concentration. No differences emerged when considering
VPA+ patients classified according to VPA total daily dose < or
> 800mg. No correlations were found between duration of VPA
exposure (months) and subcortical measures.
Past Exposure to Valproate
To evaluate possible long-term effects of VPA exposure on brain
structure, we evaluated patients who were no longer VPA users at
the time of MRI but who had been exposed to VPA in the past (n
= 27; 11 females; mean age 24.2± 3.2; time since VPAwithdrawal
6 months to 5 years). Cortical and subcortical measures of
patients with past-exposure to VPA were compared to HC and
to drug-naïve patients: there were no significant differences for
any cortical brain parcellation or for any subcortical structure.
DISCUSSION
The main study finding showed occipital lobe cortical changes,
particularly in the visual cortex, and ventricular enlargement
in people with epilepsy using VPA compared to those not
on VPA. These differences were independent of clinical and
demographic variables. Moreover, a direct comparison between
patients with past exposure to VPA and controls’ groups did
not reveal significant differences, suggesting that valproate-
related changes might be transient and reversible. Overall,
even if the retrospective cross-sectional design of this study
cannot establish a causal role of VPA on the observed brain
structural changes, the observed findings are presumably related
to VPA use and are not driven by epilepsy per se or by
generalized or focal epilepsy phenotype. Notably, these results
are consistent with previous case reports of “pseudoatrophy” and
ventricular enlargement associated with cognitive impairment
or parkinsonism in children and adults with epilepsy (12–14)
and with clinical trials evaluating the effect of valproate use in
Alzheimer’s disease patients, showing accelerated brain volume
loss and ventricular enlargement in VPA users compared to
non-users (15, 16).
Since its original discovery in France in early 60 s as an
analog of valeric acid, sodium valproate has become one of the
mainstays for the treatment of different epilepsy syndromes in
adults and children (1). However, despite its long-standing usage,
its multi-faceted mechanism of action is still matter of debate.
Sodium valproate increases gamma-aminobutyric acid
(GABA) synthesis and release and hence potentiates GABAergic
transmission in several brain regions. It also attenuates neuronal
excitation mediated by activation of N-methyl-d-aspartate
glutamate receptors. Moreover, a direct action on blocking of
voltage-dependent sodium channels was also reported (1).
The occipital, and particularly the visual cortex changes
related to VPA exposure are of particular interest considering
the established efficacy of this drug in the treatment of GGE,
and in particular to reduce the photoparoxysmal response in
photosensitive epilepsies (6), as well as its efficacy in reducing
cortical excitability in migraine (7). It is of interest that valproate
is largely used in treating patients with electroclinical syndromes
for whom the visual system has been demonstrated to be the hub
of ictogenesis. One is eyelid myoclonia with absence syndrome
(Jeavons syndrome) in which the photoparoxysmal response is
a cardinal feature of the syndrome itself. Notably, an increased
thickness of the visual cortex has been demonstrated in these
patients (compared to healthy controls and patients without
photosensitivity) as well as an increased functional connectivity
between parieto-occipital networks and the motor system (32–
34). Another such syndrome is idiopathic occipital lobe epilepsy,
a focal idiopathic epilepsy syndrome of childhood, in which the
extrastriate visual cortices are involved in spike generation and
propagation (35). Moreover, valproate has been demonstrated
to modulate (decrease) the excessive functional connectivity
between parieto-frontal and motor networks in patients with
juvenile myoclonic epilepsy, the commonest GGE syndrome in
adolescent and young adults, indicating a possible normalizing
effect of this drug (36). Recently, reduced functional connectivity
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FIGURE 4 | Volume of the lateral ventricles (means, mm3 ) in the different groups. VPA+ (*) and VPA mono (**) groups showed enlarged ventricular volumes (both right
and left ventricle) with respect to every other group. No significant differences were present for healthy controls, VPA-, and drug-naïve groups (see text and Table 3).
VPA+: epilepsy patients using valproate (in mono or polytherapy); VPA-, patients not using valproate; VPA mono, patients using valproate in monotherapy. Bars
represent the standard error of the mean.
in primary visual and parietal brain networks was noted after
administration of VPA in functional neuroimaging studies in
the baboon model of genetic generalized epilepsy, suggesting
a presumed therapeutic benefit in terms of seizure generation
inhibition (37).
Considering the clinical effects of VPA on migraine and
photosensitivity and the present findings of VPA-related
thinning of posterior cortical regions, we hypothesize that
some components of the mechanism of action of VPA are
related to cortical structural changes, whether related to its
action on GABA or ion-channels neurotransmission or not.
Interestingly, vigabatrin, an irreversible GABA-transaminase
inhibitor used as first-line treatment in children with infantile
spasms, has been demonstrated to induce reversible subcortical
alterations (age- and dose-related) in young infants (38, 39).
The most common sites for abnormal MRI signal intensity
and/or restricted diffusion were the basal ganglia, followed by
the dorsal brainstem, dentate nuclei, and thalami. No study to
our knowledge has investigated this effect by means of advanced
quantitative MRI methods.
Although growing evidence points to a probable role of VPA
in causing structural and functional brain changes, mechanisms
underlying these changes are still poorly understood. A possible
explanation involves inhibition of neurite outgrowth (40),
but also osmotic changes (41), and neurotoxicity (42) have
been hypothesized. Another proposed mechanism is through
mitochondrial dysfunction, as suggested in patients with
mitochondrial DNA mutation and VPA toxicity (43). More
recently, converging evidence suggests a possible epigenetic
effect of VPA on human central nervous system, mediated
by histone deacetylase (HDACs) dysregulation (44). Indeed,
systemic administration of valproate, a recognized global HDACs
inhibitor, induced myelination dysregulation in animals’ brain
(45, 46), suggesting that chronic exposure to valproate may
profoundly affect this process (47). Moreover, VPA treatment
produced marked alterations in the expression of multiple
genes, many of which are involved in transcription regulation,
cell survival, ion homeostasis, cytoskeletal modifications and
signal transduction (48). As suggested by Rosenzweig et al. (47)
“VPA via its biochemical, molecular and epigenetic mechanisms
may simultaneously act to promote neuronal survival and
proliferation, while also negatively affecting differentiation of
local oligodendrocyte progenitor cells.” The advent of several
new imaging techniques, including DTI or myelin-specific MRI
techniques, will enable in vivo visualization of any such effects
of VPA. Unfortunately, in our study we did not collect specific
MRI sequences to analyse white matter or tractography, but we
can speculate that our finding of bilaterally larger lateral ventricle
volume in patients taking VPA in comparison to controls’ groups
might reflect a global white matter change related to VPA
role as pan-HDACs inhibitor of (re)myelination efficiency and
homeostasis. Importantly, epigenetic effects are related to the
duration of exposure to VPA. Therefore, the putative effects
of valproate as an HDAC inhibitor could also explain the
reversibility of the cortical and subcortical structural changes that
we observed in the patients that were no longer VPA users.
Study Limitations
This study has several limitations. The first one as already
pointed is the retrospective and cross-sectional design of the
study. Therefore, a direct causation of VPA on the observed
brain structural changes cannot be established. A prospective
within-subject longitudinal study should be performed to address
this question. Second, we did not collect neurobehavioral
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measures. This prevents to correlate cortical changes revealed
by MRI and neuropsychological and behavioral features, as
suggested by previous case reports (10, 14). Other limitations
of this study concern the sample size of the different groups:
even though the sample was larger with respect to previous
MRI studies investigating AEDs effects on brain structure, it
was still limited. However, it should be noted that detailed
AED information is typically difficult to obtain in larger and
multicentre retrospective datasets. Indeed, the only other study
that evaluated with structural imaging the VPA effect in people
with epilepsy included only seven/nine subjects and all were
male (17). Finally, the duration of the disease was significantly
different between groups, being shorter in drug-naïve patients
and longer in other groups. To mitigate the influence of
disease duration, we treated this variable as a confound in all
statistical analyses. Moreover, the VPA users had shorter disease
duration with respect to non-VPA users, suggesting that it is
highly improbable that the observed VPA-related findings are
a consequence of a longer disease duration in patients exposed
to VPA.
Conclusion
We observed that occipital lobe cortical changes, particularly
in the visual cortex, are present in people with epilepsy using
VPA. These differences were independent from clinical and
demographic variables, and specific for VPA use. The fact that
these changes were not observed in patients with past exposure
to valproate may suggest reversibility. We believe these findings
are relevant both in relation to efficacy and to the adverse events
profile of VPA use in people with epilepsy. Finally, the findings of
the present study should also be taken into account as a potential
confounding factor in any MRI morphometric study in which
subjects taking VPA are included.
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